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Abstract
Objectives: To study the resistance of HDL particles to direct oxidation in respect to the distribution of HDL
particles.
Design and Methods: We studied HDL composition, subclass distribution, and the kinetics of CuSO4-induced
oxidation of total HDL and HDL3 in vitro in 36 low-HDL-C subjects and in 41 control subjects with normal HDL-C.
Results: The resistance of HDL3 to oxidation, as assessed from the propagation rate was significantly higher than
that of total HDL. The propagation rate and diene formation during HDL oxidation in vitro was attenuated in HDL
derived from low-HDL-C subjects. Propagation rate and maximal diene formation during total HDL oxidation
correlated significantly with HDL mean particle size. The propagation rate of total HDL oxidation in vitro displayed
a significant positive association with HDL2 particle mass and HDL mean particle size by multiple regression
analyses.
Conclusions: These observations highlight that the distribution of HDL subpopulations has important implications
for the potential of HDL as an anti-oxidant source.
Introduction
A strong body of epidemiological evidence associates low
levels of high density lipoprotein cholesterol (HDL-C)
with the cardiovascular disease risk [1,2]. Importantly, it
was just recently reported that HDL protects against car-
diovascular disease in both males and females, indepen-
dent on subject’s age and at all levels of risk [3].
HDL protects against atherosclerosis by several
mechanisms although the reverse cholesterol transport
plays the major role. HDL exerts anti-atherogenic actions
also via its inherent anti-oxidative and anti-inflammatory
properties [4], because it carries enzymes such as paraox-
onase 1 (PON1), which may protect against oxidation as
well as inflammation [4-6]. Recently it was also demon-
strated that apoA-I and HDL can neutralize procoagulant
properties of anionic phospholipids and thereby prevent
inappropriate stimulation of blood coagulation [7]. HDL
acts as an effective scavenger of superoxide anions [8],
and thus it can protect low density lipoprotein (LDL)
against oxidative modification in vitro [5,6,9,10]. The
interplay between LDL oxidation and atherogenesis may
provide additional opportunities for functional metrics of
HDL. Regarding the atheroprotection it is of importance
to notify that HDL particles are highly heterogeneous in
their size, structure, metabolism, and biological function.
Emerging evidence suggests that small, dense HDL3-
subspecies possess a higher capacity to protect LDL
against oxidation than large, light HDL2 particles [9-11].
Taken together, this protective action of HDL particles is
of utmost importance since oxidized LDL is considered
to be the most atherogenic species among the modified
LDLs [12].
Subjects with low HDL-C display marked changes in
their HDL composition and subclass distribution.
Previous studies indicate that larger HDL2 particles as
well as HDL mean particle size are reduced in subjects
with low HDL-C [13-16]. Notably, HDL particle size
correlates positively with HDL-C levels [15,17]. In addi-
tion, familial low-HDL-C subjects exhibit higher levels
of inflammation markers such as high-sensitivity C-reac-
tive protein (hsCRP) [18,19].
Low-HDL-C status is a typical complex disorder caused
by interaction between several genes and environmental
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factors. It is a highly prevalent condition among people
with type 2 diabetes and is one of the seminal features of
the metabolic syndrome [20,21]. Notably, low HDL-C is
the most common familial lipoprotein abnormality in
subjects with premature coronary heart disease (CHD)
[22-24]. Considering the global epidemics of type 2 dia-
betes and metabolic syndrome, the burden of low HDL-C
as a risk factor of cardiovascular disease is likely to
increase rapidly in the near future [25,26].
A growing body of evidence suggests that the capacity of
HDL to protect LDL against oxidation is compromised in
low-HDL-C subjects as compared to individuals with
normal HDL-C levels [13]. In contrast, it is still unclear
whether functional deficiency of HDL particles with
respect to direct oxidation of its lipids is linked to any
specific subclass or composition of HDL particles. This
lead us to explore the oxidation susceptibility of both total
HDL and HDL3 particles among Finnish low-HDL-C
subjects, known to have clear-cut differences in HDL sub-
species, particle compositions, and HDL mean particle size
as compared to subjects with normal HDL-C levels.
Subjects and methods
Study subjects
We recruited 36 low-HDL-C subjects and 41 healthy
control subjects with normal HDL-C levels for this study.
Low HDL-C was defined according to the Adult Treat-
ment Panel III (ATP III) of the National Cholesterol
Education Panel [21], (HDL-C < 1.03 mmol/L in men
and <1.29 mmol/L in women). Of the 36 low-HDL-C
subjects, 23 were family members from 10 low-HDL-C
families, as defined previously [27]. In addition, we
included, in the low-HDL-C group, 4 spouses from low-
HDL-C families and 9 family members with low HDL-C
from families, which did not fulfill the criteria for low-
HDL-C families [14]. The control group consisted of 16
spouses from low-HDL-C and familial combined hyperli-
pidemia (FCHL) families, and 25 normolipidemic sub-
jects from families, which did not fulfill the criteria for
familial dyslipidemias. The control subjects were healthy
with normal HDL-C levels as defined by ATPIII and did
not use any lipid medication. Subjects with diabetes mel-
litus or estrogen therapy were excluded. Of the low-
HDL-C women, 2 were postmenopausal and of the
women in the control group, 5 were postmenopausal.
Each participant filled out a standard questionnaire on
medication, drinking, and smoking habits. The smoking
status of the subjects was categorized in three groups,
current, ex-, and non-smokers. Each study subject gave a
written informed consent before participating in the
study. All samples were collected in accordance with the
Helsinki declaration, and the Ethics Committee of
the Helsinki University Central Hospital approved the
protocol.
Biochemical analyses
Venous blood samples were drawn after an overnight fast
for biochemical analyses. Serum and EDTA plasma were
separated by low-speed centrifugation and stored at -80°
C until analysis. Serum total cholesterol (TC) and trigly-
cerides (TG) were determined with an automated Cobas
Mira analyser (Hoffman-La Roche, Basel, Switzerland) by
fully enzymatic methods (Hoffman-La Roche kits
#0722138 and #0715166, respectively). Serum HDL-C
was quantified after the precipitation of apoB-containing
lipoproteins with phosphotungstic acid/magnesium
chloride (Hoffman-La Roche kit #0720674). Serum LDL
cholesterol was calculated from the Friedewald formula
[LDL cholesterol = TC-(HDL-C)-TG/2.2] [28]. Notably
TG levels of all subjects were under 4.5 mmol/l. Concen-
trations of apolipoprotein A-I (apoA-I), apolipoprotein
A-II (apoA-II) and apolipoprotein B-100 (apoB-100) were
measured by immunoturbidometric methods (for apoA-I;
Wako Chemicals GmbH, Neuss, Germany, for apoA-II;
Wako Chemicals GmbH and own polyclonal antibody
produced in rabbits against human apoA-II, and for
apoB; Orion Diagnostica, Espoo, Finland). Plasma glucose
concentration was analysed by glucose dehydrogenase
method (Precision-G Blood Glucose Testing System,
Medisense, Abbott, Illinois, USA). The level of hsCRP
was determined by a commercial kit (Konelab kit
#981798, Thermo Electron Corporation, Vantaa,
Finland). Subjects with hsCRP levels over 10 mg/L were
excluded from the calculation. Serum PON1 activities
were determined as described [29] using paraoxon as a
substrate.
Distribution and composition of HDL subfractions
HDL subclasses were isolated by ultracentrifugation, and
HDL composition was analyzed as described previously
[30]. Particle mass concentrations of the isolated HDL2
and HDL3 were calculated as the sum of concentrations
(in mg/dl) of TG, free cholesterol, cholesteryl esters
(CE), phospholipids (PL) and total protein of particles.
HDL subclass distribution and HDL mean particle size
were determined with native gradient gel electrophoresis
as previously described [31] with minor modifications.
Briefly, electrophoresis was performed by using the d ≤
1.21 kg/l ultracentrifugally isolated lipoprotein fraction
from plasma. We used Hoefer miniVE vertical electro-
phoresis system (Amersham Biosciences, San Fransisco,
CA, USA) with native 4-22% polyacrylamide gradient
gels (10×10.5 cm, PAA:BIS 19:1) prepared in the labora-
tory. Samples were electrophoresed at 125 V for
24 hours at +4°C in a running buffer (90 mM TRIS,
80 mM boric acid, and 3 mM EDTA, pH 8.53). Gels
were stained for one hour with 0.04% Coomassie blue
G-250 and destained overnight with 5% acetic acid. Gels
were densitometrically scanned with Kodak digital
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science 1D system (Eastman Kodak Company, Roche-
ster, NY, USA) and analyzed with ImageMaster™ 1D
software (version 4.00, Amersham Pharmacia Biotech,
Newcastle, UK).
We used High Molecular Weight (H.M.W.) calibration
kit from Pharmacia for standardization. The characteris-
tic molecular size intervals for HDL subclasses 2b, 2a,
3a, 3b, and 3c were used [31], and for each subpopula-
tion, the relative area under the densitometric scan is
reported. Mean HDL particle size, as the surrogate mar-
ker of the distribution of HDL subclasses, was calculated
by multiplying the mean size of each HDL subclass by
its relative area under the densitometric scan [32].
Antioxidative potential of HDL subfractions
After ultracentrifugation EDTA was immediately removed
from the HDL and HDL3 using size exclusion chromato-
graphy (PD-25 column). The pure HDL or HDL3 (100 μg
of total HDL or HDL3 protein/ml, respectively) was
incubated in the presence of 5 μmol/l (final concentra-
tion) of freshly prepared CuSO4 in a total volume of
0.2 ml at +27°C [33,34]. Conjugated diene formation
was kinetically monitored at 234 nm in temperature-
controlled spectrophotometer (Safire V2.00, Tecan
Austria GmbH, Austria) every 2 minutes until 200
minutes. Every sample was run in at least six times
and finally the mean value of the measurements was
calculated. During the kinetics of diene accumulation,
three consecutive phases were identified, the lag, the
propagation, and the decomposition phase [9,13,33-35].
For each curve, the duration of lag phase, propagation
rate and amount of dienes formed at the end of the
propagation phase (maximal dienes) were calculated as
the surrogate markers of antioxidative capacity of HDL
and HDL3. The lag time (min) was defined as the time
from the addition of CuSO4 until the intersection of
this tangent with the baseline [36]. The propagation
rate is defined as the slope of the tangent of the propa-
gation phase and is expressed as nmol dienes formed/
min per mg of total HDL or HDL3 protein. The maxi-
mum amount of conjugated dienes formation,
expressed as nmol dienes formed/mg of total HDL or
HDL3 protein, was determined as the height of maxi-
mum absorbance above baseline.
Statistical Analysis
Statistical comparisons of clinical and biochemical para-
meters were performed with SAS ver.8.02 (SAS Institute
Inc.). Results are expressed as means ± SD for continu-
ous variables and as frequencies or percentages for cate-
gorical variables. Before the analyses, continuous
variables with skewed distribution were log10 trans-
formed, but the values in text, tables and figures are
presented as nontransformed original data. Continuous
variables were compared between the groups by general
linear model, analysis of covariance (ANCOVA). Sex
was coded as men = 1, women = 0. Smoking status was
coded as current = 2, past = 1, and never = 0. Compari-
son of three oxidation markers between HDL3 and total
HDL was done using the Wilcoxon rank-sum test.
P < 0.05 was considered significant (two-tailed). The
frequency distribution of the categorical variables was
compared between the groups with the Chi-square test.
The relationships of biochemical and clinical character-
istics were examined by Pearson’s correlation and Spear-
man correlation analysis, as appropriate. Also, multiple
stepwise backward regression analyses were performed
to investigate associations of propagation rate and maxi-
mal dienes of oxidation as dependent variables. Indepen-
dent variables were removed from the model until
the best-fitting model with the maximum adjusted mul-
tiple R2 was achieved. ApoA-II and HDL-C were not
included in the same model, because these were highly
correlated to apoA-I. For the same reason, LDL-C and
apoB, or CE/TG ratio of HDL2 and HDL2 particle mass
concentrations, or CE/TG ratio of HDL3 and HDL3 par-
ticle mass concentrations were not included in the same
model.
Results
Clinical characteristics of the study subjects
The clinical characteristics of the study subjects are pre-
sented in Table 1. Twelve of the low-HDL-C subjects
had CHD. The percentage of current smokers was
slightly higher among the low-HDL-C subjects. After
adjustment for age, sex, and smoking status, the low-
HDL-C subjects had significantly higher BMI, waist, TG,
and hsCRP. As expected and based on the selection cri-
teria TC, apoA-I and A-II levels were reduced in the
low-HDL-C subjects. However, PON1 activity was not
different between the two groups.
The protein/lipid composition and the distributions of
HDL subspecies in the study subjects are presented in
Table 2. After adjustment for age, sex, and smoking sta-
tus, the particle mass concentrations and CE/TG ratio
of both HDL2 and HDL3 were markedly lower in the
low-HDL-C subjects than those in control subjects. The
HDL2 particles of the low-HDL-C subjects contained
relatively more TG and total protein but less CE and
phospholipids than those of the control subjects. Simi-
larly, HDL3 from the low-HDL-C subjects contained
relatively more TG but less CE than HDL3 in the con-
trol group. The proportion of HDL2b particles was sig-
nificantly lower, whereas that of HDL3a and HDL3b were
significantly higher in the low-HDL-C subjects than in
the control subjects. HDL mean particle size was mark-
edly smaller in the low-HDL-C subjects as compared to
that in the control subjects.
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Table 1 Clinical characteristics of the study subjects according to the criteria of ATPIII
Low-HDL-C Control P
N (Men/Women) 36 (25/11) 41 (19/22) 0.027
Current smoking (%) 14 (40.0) 9 (22.0) 0.189
Coronary heart disease (%) 12 (34.3) 0 (0)
Age (years) 43.7 ± 13.7 45.6 ± 12.7 0.802
Systolic blood pressure (mmHg) 129 ± 18 128 ± 16 0.607
Diastolic blood pressure (mmHg) 80 ± 11 81 ± 9 0.985
Body mass index (kg/m2) 26.2 (23.9 - 29.0) 23.7 (21.4 - 26.5) 0.001
Waist circumference (cm) 96.0 ± 10.8 84.7 ± 10.7 0.001
TC (mmol/l) 4.22 (3.69 - 5.17) 5.04 (4.31 - 5.60) 0.003
TG (mmol/l) 1.22 (1.02 - 1.62) 0.85 (0.72 - 1.08) <0.0001
LDL-C (pmol/l) 2.68 (2.15 - 3.53) 2.79 (2.33 - 3.29) 0.316
HDL-C (pmol/l) 0.93 (0.81 - 0.99) 1.62 (1.35 - 1.91) <0.0001
ApoA-I (mg/dl) 110 (104 - 117) 143 (129 - 159) <0.0001
ApoA-II (mg/dl) 35 (29 - 40) 37 (32 - 40) 0.035
ApoB (mg/dl) 96 (83 - 111) 88 (78 - 106) 0.657
PON1 activity (nmol/min/ml) 155 (106-211) 133 (92-265) 0.614
hsCRP (mg/l) 1.03 (0.51 - 2.91) 0.46 (0.24 - 1.71) 0.007
Data are expressed as means ± SD or median (lower and upper quartile). The two P values from the top are evaluated using c2 tests. Other data are adjusted for
age, sex, and smoking status.
Table 2 Composition (weight %) and distribution (%) of HDL derived from the low-HDL-C and control subjects
Low-HDL-C Control P
HDL2 particle mass (mg/dl) 68 (58 - 90) 153 (106 - 213) <0.0001
HDL2 CE/TG ratio 3.17 (2.64 - 4.22) 6.00 (4.48 - 7.34) <0.0001
HDL2 TG (% of HDL2) 5.6 (4.2 - 6.6) 3.4 (2.8 - 4.5) <0.0001
HDL2 CE (% of HDL2) 18.9 (16.2 - 20.6) 20.8 (19.2 - 22.3) 0.002
HDL2 free cholesterol (% of HDL2) 4.7 (4.2 - 6.0) 5.0 (4.6 - 5.6) 0.573
HDL2 phospholipids (% of HDL2) 24.0 (22.0 - 26.0) 27.9 (24.8 - 29.5) 0.001
HDL2 protein (% of HDL2) 46.3 (43.1 - 49.4) 42.5 (39.9 - 46.2) 0.0007
HDL3 particle mass (mg/dl) 209 (191 -226) 242 (214 - 266) 0.0001
HDL3 CE/TG ratio 4.64 (3.48 - 5.96) 7.07 (5.61 - 8.80) <0.0001
HDL3 TG (% of HDL3) 3.7 (3.0 - 4.3) 2.5 (2.1 - 3.1) <0.0001
HDL3 CE (% of HDL3) 16.8 (14.9 - 18.8) 17.5 (16.5 - 19.1) 0.039
HDL3 free cholesterol (% of HDL3) 2.3 (2.0 - 2.5) 2.4 (2.2 - 2.6) 0.848
HDL3 phospholipids (% of HDL3) 22.2 (20.2 - 23.3) 22.3 (21.0 - 23.2) 0.815
HDL3 protein (% of HDL3) 54.9 (51.6 - 58.1) 55.6 (51.7 - 57.7) 0.984
HDL2b (%) 15.1 ± 5.0 30.1 ± 10.4 <0.0001
HDL2a (%) 27.2 ± 5.2 26.3 ± 7.0 0.763
HDL3a (%) 34.9 ± 4.4 27.7 ± 6.4 <0.0001
HDL3b (%) 18.5 ± 5.4 10.9 ± 4.5 <0.0001
HDL3c (%) 5.3 ± 2.7 4.1 ± 3.0 0.422
HDL mean particle size (nm) 8.98 ± 0.21 9.44 ± 0.35 <0.0001
Data are expressed as means ± SD or median (lower and upper quartile). TG: triglycerides, CE: cholesteryl esters. Statistical significances were adjusted for age,
sex, and smoking status. HDL subclasses were isolated by ultracentrifugation and distribution of HDL subclasses as well as particle size were analyzed by native
gradient gel electrophoresis.
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The resistance of total HDL and HDL3 particles to the in
vitro oxidation
Both the propagation rate and maximal diene formation
during total HDL oxidation were significantly higher than
those observed during HDL3 oxidation in both control
subjects and low-HDL-C subjects. The lag time, however,
did not differ between HDL3 and total HDL oxidation in
either control or low-HDL-C subjects (Table 3).
After adjustment for age, sex, and smoking status,
propagation rate and maximal diene formation during
oxidation of total HDL derived from the low-HDL-C
subjects were significantly lower than the corresponding
values with HDL isolated from the control group
(Table 3). The lag time values of total HDL oxidation,
however, were not different between the two groups.
Even after further adjustment for TC, apoA-I, apoA-II,
TG, BMI, waist, or hsCRP, the differences in the propa-
gation rate of total HDL between the two groups
remained significant (data not shown). In contrast, all
the surrogate markers of HDL3 oxidation were compar-
able between the two groups (Table 3).
The impact of HDL composition, particle size and
systemic inflammation on the resistance of HDL to in
vitro oxidation
Relationships between the three surrogate markers of
HDL oxidation in vitro and HDL mean particle size are
presented in Figure 1. HDL mean particle size showed
strong positive correlation with the propagation rate and
the maximal dienes formed during total HDL oxidation
(r = 0.689, P < 0.0001, and r = 0.598, P < 0.0001, respec-
tively). As certain plots of the control and low-HDL-C
subjects overlap we analyzed the relationships in a
pooled study sample. When the groups were analyzed
separately HDL mean particle size correlated signifi-
cantly in the control subjects with the propagation rate
(r = 0.557, P = 0.0002), and with the maximal dienes
formed during total HDL oxidation (r = 0.531,
P = 0.0004). Similarly, the low-HDL-C subjects showed
a strong positive correlation between HDL mean particle
size and the propagation rate (r = 0.407, P = 0.016), but
the correlation with the maximal diene formation did
not reach statistical significance (r = 0.281, P = 0.103).
During oxidation of the HDL3 particles, a relationship
existed between HDL mean particle size and the propa-
gation rate among low HDL subjects (r = 0.451,
P = 0.007). However, among control subjects or in the
pooled study sample, no relationships existed between
HDL mean particle size and the propagation rate or the
maximal diene levels during oxidation of the HDL3 par-
ticles. In addition, the lag time values of total HDL or
HDL3 during Cu-mediated oxidation did not correlate
significantly with HDL mean particle size.
Finally, we performed stepwise regression analyses to
determine the relationships between different variables
and the markers of total HDL (Table 4). The propaga-
tion rate of total HDL oxidation was significantly asso-
ciated with HDL2 particle mass, HDL mean particle size,
Table 3 Comparison of the parameters of HDL oxidation between HDL particles derived from the low-HDL-C and
control subjects
Low-HDL-C Control P value
Lag time (minute)
Total HDL oxidation 66.47 69.19 0.326
(56.35 - 96.54) (56.16 - 78.50)
HDL3 oxidation 69.40 64.04 0.206
(55.75 - 96.51) (54.44 - 82.45)
P value 0.427 0.176
Propagation rate (nmol/mgHDL or HDL3/min)
Total HDL oxidation 1.242 1.543 <0.0001
(1.097 - 1.362) (1.431 - 1.795)
HDL3 oxidation 1.032 1.022 0.533
(0.924 - 1.123) (0.807 - 1.159)
P value <0.0001 <0.0001
Maximal dienes (nmol/mgHDL or HDL3)
Total HDL oxidation 86.67 107.47 0.002
(76.38 - 103.31) (97.62 - 114.87)
HDL3 oxidation 71.47 71.57 0.646
(63.26 - 78.45) (60.89 - 84.22)
P value <0.0001 <0.0001
Data are expressed as median (lower and upper quartile). Statistical significances were adjusted for age, sex, and smoking status between low HDL and control
subjects.
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Figure 1 Relationships between HDL mean particle size and oxidation parameters of total HDL and HDL3 derived from the low-HDL-C
and control subjects. Upper panels: relationship between HDL mean particle size and lag time; Middle panels: relationship between HDL mean
particle size and propagation rates; Lower panels; relationship between HDL mean particle size and maximal diene formation.
Shuhei et al. Lipids in Health and Disease 2010, 9:104
http://www.lipidworld.com/content/9/1/104
Page 6 of 10
and hsCRP. The maximal diene formation in total HDL
oxidation was significantly associated with HDL mean
particle size. In contrast, the propagation rate during
HDL3 oxidation was significantly associated only with
hsCRP. The maximal diene formation during HDL3 oxi-
dation had no association with any of the measured
variables.
Discussion
Here we report the susceptibility of total HDL and
HDL3 particles to Cu-mediated oxidation in vitro. HDL
particles were isolated from the well-characterized Fin-
nish low-HDL-C subjects and from the healthy subjects
with normal HDL-C concentrations. Previous studies
have explored the effect of HDL to protect LDL from
oxidation but data on the susceptibility of HDL itself to
oxidation are sparse. To the best of our knowledge, this
is the first study to explore the impact of HDL composi-
tion, size, and hsCRP as a surrogate marker of systemic
inflammation, on direct oxidation of HDL particles in
vitro using widely used copper oxidation method of
Esterbauer [33] that initiates free radical reactions
within HDL particles. Unexpectedly, we found that the
propagation rate and diene formation during HDL oxi-
dation in vitro was attenuated in the low-HDL-C sub-
jects. Also, we demonstrated that the resistance of
HDL3 particles to oxidation is higher than that of total
pool of HDL particles. This suggests that HDL3 particles
are less prone to oxidation than HDL2 in vitro. In addi-
tion, the resistance of HDL particles to oxidation is
affected by HDL lipid/apolipoprotein composition,
HDL-associated proteins other than apolipoproteins,
subclass distribution, and systemic inflammation.
Interestingly, HDL particles are major carriers of lipid
peroxides in circulation [36]. In fact, HDL3 particles
possess higher PON1 activity [9] as compared with
HDL2 particles. PON1 is considered to be a major
protein conferring anti-oxidant activity of HDL
[6,37,38]. Accordingly, HDL3 particles were more resis-
tant than total HDL particles to direct Cu-oxidation
based on the difference in the propagation rate in both
groups, because HDL includes both HDL2 and HDL3. In
addition, compared to HDL3 particles, the increase in
maximal diene formation of total HDL particles was
apparent in both groups. These results support previous
data indicating that small, dense HDL particles have
more capacity to protect LDL against oxidation than
large HDL particles [9-11]. A lower propagation rate
and less diene formation are commonly considered to
be an indicator of increased antioxidant capacity [33,34].
In line with this it has been reported that large, less-
dense HDL subspecies and high HDL concentrations
tended to enhance more diene production than small,
dense HDL particles [9,34,35]. In this context it is
important to notify that small, dense HDL3 particles
seem to have compromised anti-oxidative activity in
subjects with type 2 diabetes and the metabolic
syndrome [39,40]. The present study groups did not
contain any subjects with diabetes. However, the low-
HDL-C subjects had features of the metabolic syndrome
such as elevated waist circumference and inflammation.
The fact that the resistance of total HDL particles to oxi-
dation in vitro from the control subjects was significantly
lower than that from the low-HDL-C subjects is a para-
dox. This apparent contradiction could be explained by
the dramatic difference of HDL2 concentrations between
the two groups. The concentrations of HDL2 particles in
the purified HDL fraction from the control subjects are
expected to be high compared to HDL from the low-
HDL-C subjects at the same level of HDL protein since
variability in HDL-C levels mainly reflects changes in the
large HDL particles [41]. Accordingly, after adjustment for
the ratio of HDL2 and HDL3 protein, the difference of
maximal diene formation during total HDL oxidation
between the two groups disappeared (data not given).
Notably, the propagation rate of total HDL oxidation was
inversely correlated with HDL2 particle mass and HDL
particle size. Nevertheless, the susceptibility of HDL3 to
oxidation in the low-HDL-C subjects was not different
from that seen in HDL3 derived from the control subjects.
This result may be explained by the fact that PON1 activ-
ity, affecting HDL3 anti-oxidant activity [9], was not differ-
ent between the two groups in our study.
A recent paper using hypochlorous acid (HOCL) as a
potent oxidant demonstrated that structural and physio-
chemical differences between HDL2 and HDL3 subclasses
per se did not affect their intrinsic susceptibility to oxida-
tive attack by HOCL. Instead it was dependent on the
concentration (particle number or mass) employed [42].
Human HDL proteome studies have revealed that HDL-
associated proteins are distributed in specific patterns
Table 4 Stepwise regression analyses of the parameters
of total HDL and HDL3 oxidation in the combined
population of low HDL and control subjects
Propagation rate Maximal dienes
b P b P
Total HDL oxidation
HDL2 particle mass (mg/dl) 0.390 0.005 NE -
HDL mean particle size (nm) 0.325 0.021 0.582 <0.001
hsCRP (mg/l) -0.205 0.005 NE -
HDL3 oxidation
hsCRP (mg/l) -0.321 0.021 NE -
BMI and TG were included. b: Standardized regression coefficient. NE: Factor
that did not enter the final model. The adjusted multiple R2 of the regression
model of propagation rate and maximal dienes of total HDL oxidation was
0.556 and 0.321, respectively. The adjusted multiple R2 of the regression
model of propagation rate and maximal dienes of HDL3 oxidation was 0.062
and -0.008, respectively.
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across HDL subpopulations, and the noticed potent anti-
oxidative activity of HDL3 particles is characterized by a
proteome of distinct composition [43]. Taken together
this part, HDL2 is more readily oxidized than HDL3,
most likely because of its higher content of oxidable
lipids and lower content of potentially protective
proteins.
As expected in the low-HDL-C subjects, the lipid core
compositions of HDL2 and HDL3 displayed clear
changes such as enrichment of TG and depletion of CE.
Importantly, HDL2 was also depleted in phospholipids
and the amount of apolipoproteins relative to phospholi-
pids was increased in the low-HDL-C subjects. These
changes in physicochemical properties of HDL particles
may modify the resistance of HDL subfractions to oxi-
dation. Recently, phospholipid depletion has been shown
to decrease the size of reconstituted HDL particles [44].
Therefore, the low susceptibility of HDL to oxidation in
the low-HDL-C subjects may be due to the composi-
tional changes specifically in the HDL2 subclass.
A short lag time during oxidation is considered to
reflect enhanced susceptibility to oxidation. In our
study, there were no differences in lag time of HDL3
and total HDL particles between the two groups. Our
data are in line with other observations that the impair-
ment of HDL to protect LDL against in vitro oxidation
using HDL derived from subjects with low-HDL-C or
metabolic syndrome was observed only in those oxida-
tion parameters displayed after the lag phase [13,40].
Although the detailed mechanisms responsible for the
antioxidative properties inherent for HDL particles are
not well understood, both copper and HDL concentra-
tions used in the experiments in vitro may modulate the
oxidation capacity of HDL subfractions [9,35,45]. HDL
particles are easily oxidized by several mechanisms
including myeloperoxidase production that may be criti-
cal in vivo to produce dysfunctional HDL.
There are certain limitations in the present study and
therefore extrapolations of our findings should be made
with appropriate caution. It is clear that there are differ-
ences in oxidation kinetics depending on the oxidation
reagent used. The antioxidant properties of HDL are mod-
ified by the availability of several HDL associated mole-
cules such as a-tocopherol, LCAT, and estrogen [46-49]
that were not measured in this study. Unfortunately we
were not able to measure directly the oxidation of HDL2
particles in vitro due to a lack of material. As twelve
patients with CHD were included in the low-HDL subjects
a possibility exists that some medication such as atorvasta-
tin [50,51] might modify the antioxidative capacity of HDL
particles. However, the results when examined via exclud-
ing these twelve subjects did not differ significantly (data
not shown).
The small sample size including both genders in the
same analyses is recognized as a limitation of this study.
However, we aimed to minimize the confounding effect
of mixed gender population by gender adjustment in the
statistical analyses. The recruitment of the study sub-
jects from families may affect the results but the possi-
ble confounding factor was considered relative as the
mean family size was small (2).
Although recruited from the database of familial dysli-
pidemias, the low-HDL-C subjects display additional
features of metabolic syndrome such as elevated waist
circumference and hsCRP. This is in line with our pre-
vious finding on familial low-HDL-C subjects [18]. As
an isolated low-HDL-C state is rare, the cardiovascular
burden of low HDL-C will focus on the subjects with
the features of metabolic syndrome.
In summary, HDL lipid and protein distributions
affect the antioxidative capacity of HDL2 and HDL3 as
well as systemic inflammation of HDL subfractions.
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